Authors

Going Beyond Compliance: Early Adoption of FDA’s Quality Management Maturity Program—and the Practical Considerations for Executives

An examination of proactive preparedness and readiness review for future enrollment in the agency’s QMM program—now in the pilot stage as an effort to incentivize pharma manufacturers to achieve a more mature state of quality culture.

Taking Advantage of ‘Hidden Gem’ Talent Hubs

How to optimize a pharma location strategy in unheralded but rich regions for biotech talent around the world.

HEOR: From Proving Product Value to Proving Its Own Worth

The recent shift in Health Economics and Outcomes Research functions across major pharmaceutical companies highlights a lack of understanding of its value.

Navigating the EU’s Joint Clinical Assessment

Pathways to success for this key component of Europe’s new HTA regulation, where thinking beyond the purely technical will be critical.

From Blockbusters to Black Holes: Pharma Launch Strategy in the Age of Technology and AI

Pharma Forecasting: Key Markets Investors Can’t Ignore

The importance of expanding your pharma sales forecasting horizon beyond the US. Learn how to effectively navigate country-specific regulatory red flags.

Driving Field Excellence with AI-Enhanced Rep Support

The Situation We Faced: Aaron Cowley, CSO, Recipharm Advanced Bio, Discusses Vision to Cut Biomanufacturing Timelines, Transform Continuous Manufacturing

A new unified approach to process analytical technologies from Recipharm Advanced Bio aims to replace fragmented, off-line testing with integrated real-time analytics—cutting development and release timelines by up to 50% while aligning with FDA-backed continuous manufacturing initiatives and a multibillion-dollar global PAT market opportunity.

Pharmaceutical Executive Daily: The Launch of TrumpRx

In today’s Pharmaceutical Executive Daily, TrumpRx officially launches, the FDA moves against mass marketing of illegal copycat drugs, and AI emerges as a force multiplier for small and mid-size biotech companies.

AI-Enabled Benchmarking: Transforming Performance Measurement for Pharma Brands

Market dynamics boost the need and urgency for more sophisticated benchmarking strategies.

Driving Field Excellence with AI-Enhanced Rep Support

Are DTC Programs Treating a Symptom or Cause of High Drug Prices?

Jesse Mendelsohn, executive vice president at Model N, discusses the broader issues impacting drug prices.

Abu Dhabi Reinforces Global Leadership in Healthcare Innovation with High-Level US Visit

During a high-level US visit, the Department of Health—Abu Dhabi signed strategic agreements with Abbott, Boehringer Ingelheim, and Sanofi to boost pharmaceutical manufacturing, expand vaccine development, and advance digital health and clinical research.

How Pharma’s Checks and Balances Can Help Fight Its Public Perception

What can we do to prevent such blatant black eyes to the industry so many of us love?

Future-Proofing CRM Investments in Life Sciences: Observations from Dreamforce 2024

The future is bright with AI-powered innovations, but migration presents significant risks, including data loss, increased costs, and disruption to business operations.

Measuring the ROI of SPP Adherence Programs

Can deeper data from specialty pharmacy providers bolster both patient outcomes and financial returns?

ROI and Rare Disease: Retooling the ‘Gene’ Value Machine

Framework proposes three strategies designed to address the unique challenges of personalized and genetic therapies for rare diseases—and increase the probability of economic success for a new wave of potential curative treatments for these conditions.